Evaluation of Soluble CD30 as an Immunologic Marker in Heart Transplant Recipients

Activated Effector and Memory T Cells Contribute to Circulating sCD30: Potential Marker for Islet Allograft Rejection

“…Our results of sCD30 measurement in animal models of islet transplant as well as preliminary results from human islet recipients strongly suggest that prior sensitization to alloantigens can lead to an increase in active memory T cells which continue to shed sCD30 into the circulation. This agrees with the results published by Spiridon et al demonstrating that memory T cells may be a source for circulating sCD30 (30) and alloantigen-specific memory CD4 T cells may be a source for sCD30 in the circulation of po-tential islet allograft recipients. This also suggests that in the event a patient need multiple islet transplants at different time points, sCD30 may be a useful marker to detect sensitization to the potential donor alloantigens.…”

Soluble CD30 Levels in Recipients Undergoing Heart Transplantation Do Not Predict Post-transplant Outcome

“…These results contrast with those of Frisaldi et al, 15 who suggested that pre-transplant serum sCD30 levels Ͼ30 U/ml were associated with reduced recipient survival, whereas, in the present study, sCD30 levels were not predictive of allograft rejection. Our findings are consistent with those of Spiridon et al 16 and Nikaein et al,17 who reported that high serum sCD30 had no effect on overall patient survival, although the latter group noted that serum sCD30 levels Ն90 U/ml were associated with a reduction in post-transplant infection rate.…”

“…[5][6][7][8][9] However, the utility of sCD30 as a predictor for renal transplant outcome has not been supported by all studies, 10 -14 and there is little information as to whether pretransplant levels of sCD30 are predictive of outcome after cardiac transplantation. [15][16][17] Herein we report the results of a large single-center study evaluating the clinical usefulness of pre-transplant serum sCD30 levels as a prognostic marker of heart allograft rejection and recipient survival.…”

The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses

“…CD30 has also been associated with development of Th2 cell-type responses in autoimmunity, and sCD30 is being analyzed as a predictive biomarker to manage transplant patient care. Studies testing pre-transplant levels of sCD30 in heart and kidney transplant candidates have concluded that higher sCD30 is predictive of reduced infection risk (Nikaein et al, 2007; Spiridon et al, 2006; Spiridon et al, 2008), while post-transplant analyses associate high sCD30 levels with increased risk of infection in heart transplant patients (Heikal et al, 2013) and eventual rejection in heart, kidney, and liver transplant patients (Bharat et al, 2007; Grenzi et al, 2015; Heikal et al, 2013; Wang et al, 2012). Quantifying soluble CD30 levels may help clinicians improve patient care by identifying patient populations that require different interventions.…”